DE69921138D1 - Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel - Google Patents

Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel

Info

Publication number
DE69921138D1
DE69921138D1 DE1999621138 DE69921138T DE69921138D1 DE 69921138 D1 DE69921138 D1 DE 69921138D1 DE 1999621138 DE1999621138 DE 1999621138 DE 69921138 T DE69921138 T DE 69921138T DE 69921138 D1 DE69921138 D1 DE 69921138D1
Authority
DE
Germany
Prior art keywords
cytotoxic
system containing
antineoplastic agent
releasing system
homeobox peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE1999621138
Other languages
English (en)
Other versions
DE69921138T2 (de
Inventor
Peter Martin Fischer
Shudong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of DE69921138D1 publication Critical patent/DE69921138D1/de
Publication of DE69921138T2 publication Critical patent/DE69921138T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Refuse Collection And Transfer (AREA)
  • Threshing Machine Elements (AREA)
DE69921138T 1998-07-03 1999-06-22 Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel Expired - Fee Related DE69921138T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9814527.9A GB9814527D0 (en) 1998-07-03 1998-07-03 Delivery system
GB9814527 1998-07-03
PCT/GB1999/001957 WO2000001417A1 (en) 1998-07-03 1999-06-22 Delivery system

Publications (2)

Publication Number Publication Date
DE69921138D1 true DE69921138D1 (de) 2004-11-18
DE69921138T2 DE69921138T2 (de) 2005-11-24

Family

ID=10834959

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69921138T Expired - Fee Related DE69921138T2 (de) 1998-07-03 1999-06-22 Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel

Country Status (13)

Country Link
US (2) US6472507B1 (de)
EP (1) EP1093383B1 (de)
JP (1) JP2002519392A (de)
AT (1) ATE279210T1 (de)
AU (1) AU756014B2 (de)
CA (1) CA2333145C (de)
DE (1) DE69921138T2 (de)
DK (1) DK1093383T3 (de)
ES (1) ES2230860T3 (de)
GB (2) GB9814527D0 (de)
HU (1) HUP0300246A3 (de)
IL (1) IL140650A0 (de)
WO (1) WO2000001417A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
ATE419273T1 (de) * 1998-11-13 2009-01-15 Cyclacel Ltd Translokationsvektoren abgeleitet von der antennapedia homeodomain helix 3
WO2000038733A1 (en) 1998-12-24 2000-07-06 Ucb S.A. Peptidic product, process and composition
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
DE19933492B4 (de) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
US6864355B1 (en) * 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US7049395B2 (en) 2000-05-02 2006-05-23 Yale University Anti-inflammatory compounds and uses thereof
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
FR2816845B1 (fr) 2000-11-20 2006-10-20 Centre Nat Rech Scient Vecteurs de transport a travers un epithelium a jonctions serrees
DE60239097D1 (de) 2001-03-02 2011-03-17 Gpc Biotech Ag Drei-hybrid-assaysystem
US20050181474A1 (en) * 2002-01-30 2005-08-18 Frank J. Giordano Transport peptides and uses therefor
PT1583562E (pt) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, compostos relacionados, e suas utilizações
FR2849603B1 (fr) * 2003-01-07 2006-09-08 Centre Nat Rech Scient Composition pour le transport intracellulaire de macromolecules ou particules biologiques
US20060178297A1 (en) * 2003-01-28 2006-08-10 Troy Carol M Systems and methods for silencing expression of a gene in a cell and uses thereof
EP2662087A1 (de) * 2003-04-22 2013-11-13 Ipsen Pharma Somatostatin-vektoren
JP2007531705A (ja) * 2003-05-20 2007-11-08 セルペップ ソシエテ アノニム 増大した活性および細胞膜親和性を有する修飾抗ウイルス性ペプチド
US7458683B2 (en) 2003-06-16 2008-12-02 Amo Manufacturing Usa, Llc Methods and devices for registering optical measurement datasets of an optical system
US7342114B2 (en) 2003-07-01 2008-03-11 California Pacific Medical Center Podophyllotoxin derivatives
US7790150B2 (en) * 2003-09-05 2010-09-07 The General Hospital Corporation Dual phase drug release system
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005040193A2 (en) * 2003-10-20 2005-05-06 The Regent Of The University Of California Synthetic peptides that cause f-actin bundling and block actin depolymerization
US20050209147A1 (en) * 2004-01-16 2005-09-22 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of RhoA signaling
US8034762B2 (en) * 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
EP1796708A4 (de) 2004-09-02 2009-07-08 Cognosci Inc Verbesserte apo-e-analoge und verwendungsverfahren dafür
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
DK1842557T3 (da) 2004-12-22 2013-12-02 Nitto Denko Corp Lægemiddelbærer og lægemiddelbærerkit til inhibition af fibrose
CA2597958C (en) 2005-02-18 2019-01-15 Angiochem Inc. Molecules for transporting a compound across the blood-brain barrier
DK2433653T3 (da) 2005-07-15 2019-08-19 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
BRPI0709447A2 (pt) * 2006-03-30 2011-07-12 Diatos Sa conjugado, composição farmacêutica, uso e composto
JP5313867B2 (ja) * 2006-03-30 2013-10-09 ドライス ファーマシューティカルズ，インコーポレイティド カンプトテシン−細胞透過性ペプチド複合体及びそれを含む医薬組成物
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2207570A2 (de) 2007-09-14 2010-07-21 Nitto Denko Corporation Arzneimittelträger
TW200932274A (en) 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
EP2252314B1 (de) 2008-02-27 2014-04-09 Temple University - Of The Commonwealth System of Higher Education Leptin-agonist und anwendungsverfahren
KR101585046B1 (ko) * 2008-02-28 2016-01-13 도레이 카부시키가이샤 경비 투여용 의약 조성물
CN102105135B (zh) 2008-05-23 2016-08-24 英属哥伦比亚大学 用于脂质体纳米颗粒的修饰的药物
WO2010033207A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
JP2012505637A (ja) 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド Ｇｌｐ−１アゴニストのコンジュゲート及びその使用
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
FR2941230B1 (fr) 2009-01-19 2011-03-18 Centre Nat Rech Scient Polypeptides d'adressage specifique a des cellules-cibles d'otx2
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
WO2010138955A2 (en) 2009-05-29 2010-12-02 University Of Florida Research Foundation, Inc. Methods and compositions for treating neoplasia
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
GB201001602D0 (en) 2010-02-01 2010-03-17 Cytovation As Oligopeptidic compounds and uses therof
JP5757497B2 (ja) * 2010-10-06 2015-07-29 公立大学法人大阪府立大学 シガトキシン類ｃｔｘ１ｂおよび５４−デオキシ−ｃｔｘ１ｂを認識するモノクローナル抗体およびそれを用いるシガトキシン類検出キット
WO2013036931A1 (en) * 2011-09-08 2013-03-14 Western University Of Health Sciences Targeted liposomes in cancer therapy
CN103083239B (zh) * 2012-12-26 2015-11-25 中国人民解放军第四军医大学 一种蟾毒灵脂质体及其制备方法和应用
GB201318954D0 (en) * 2013-10-28 2013-12-11 Cupid Peptide Company Ltd Cell transport
EP3288577B1 (de) 2015-05-01 2021-10-27 Allysta Pharmaceuticals, Inc. Adiponectin-peptidomimetika zur behandlung von augenerkrankungen
GB201507722D0 (en) 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Anti-bacterial agents and their use in therapy
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
US10087194B2 (en) 2015-10-27 2018-10-02 California Pacific Medical Center Podophyllotoxin derivatives and their use
CN106937529B (zh) 2015-10-27 2021-02-05 加州太平洋医疗中心 鬼臼毒素衍生物及其应用
WO2018085836A1 (en) 2016-11-07 2018-05-11 Colorado State University Research Foundation Anti-hiv peptides
CN110563739A (zh) * 2018-06-05 2019-12-13 薪火炙药(北京)科技有限公司 具有选择性抗肺癌作用的鬼臼毒素类化合物p-x及其制备方法和应用
GB201915454D0 (en) 2019-10-24 2019-12-11 Norwegian Univ Sci & Tech Ntnu Antibacterial bone cement and uses thereof
KR102397922B1 (ko) * 2020-02-19 2022-05-13 서울대학교 산학협력단 신규한 종양-관련 항원 단백질 olfm4 및 이의 용도
GB202006699D0 (en) 2020-05-06 2020-06-17 Therapim Pty Ltd Dosage regimen
GB202008888D0 (en) 2020-06-11 2020-07-29 Norwegian Univ Of Science And Technology (Ntnu) Peptides for sepsis treatment
EP4281034A1 (de) 2021-01-24 2023-11-29 Forrest, Michael, David Inhibitoren der atp-synthase kosmetische und therapeutische verwendungen

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US5043329A (en) * 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
DE3836971C1 (de) * 1988-10-31 1990-05-17 Weck, Wolfgang, Dr.Med., 6990 Bad Mergentheim, De
US5888762A (en) * 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
FR2662698A1 (fr) 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
DE69126592T2 (de) 1990-10-15 1998-01-08 Tecnogen Scpa Nicht-lineare Peptide, die hydropatisch komplementär zu bekannten Aminosäuresequenzen sind, Verfahren zur Herstellung und Verwendung davon
WO1993022343A1 (en) * 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
US6344436B1 (en) 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
WO1998013059A1 (en) * 1996-09-27 1998-04-02 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
US5929042A (en) 1997-03-03 1999-07-27 The Trustees Of Columbia University In The City Of New York Antisense compounds which prevent cell death and uses thereof
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
AU741546B2 (en) * 1997-07-24 2001-12-06 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
US5823345A (en) * 1997-07-24 1998-10-20 Berry Plastics Corporation Stackable receptacle assembly for pourable products
GB9718609D0 (en) * 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
US6015787A (en) * 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system

Also Published As

Publication number Publication date
US6992169B2 (en) 2006-01-31
US6472507B1 (en) 2002-10-29
ATE279210T1 (de) 2004-10-15
DK1093383T3 (da) 2005-02-14
JP2002519392A (ja) 2002-07-02
ES2230860T3 (es) 2005-05-01
DE69921138T2 (de) 2005-11-24
CA2333145C (en) 2008-03-25
AU4519899A (en) 2000-01-24
AU756014B2 (en) 2003-01-02
EP1093383B1 (de) 2004-10-13
GB9914577D0 (en) 1999-08-25
GB2340121B (en) 2000-09-06
WO2000001417A1 (en) 2000-01-13
GB2340121A (en) 2000-02-16
HUP0300246A2 (en) 2003-05-28
CA2333145A1 (en) 2000-01-13
IL140650A0 (en) 2002-02-10
HUP0300246A3 (en) 2005-09-28
EP1093383A1 (de) 2001-04-25
GB9814527D0 (en) 1998-09-02
US20030119735A1 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
DE69921138D1 (de) Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
EE200000380A (et) 11ß-halogeno-7(alfa)-asendatud östratrieenid, neid 11ß-halogeno-7(alfa)-asendatud östratrieene sisaldavate farmatseutiliste preparaatide valmistamise meetodid ja nende kasutamine ravimite valmistamiseks
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
ATE343969T1 (de) Beschichtete medizinische geräte
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
DK0584001T3 (da) Anvendelse af taxol til fremstilling af et medikament til behandling af cancer
HUP0300290A2 (hu) Érkárosító hatású kombinácíós készítmény és terápia
HK1021539A1 (en) Androstene derivatives.
HUP0001136A2 (hu) Limfatikus tumorok kezelésére szolgáló gyógyszerkészítmények
DE19580261D2 (de) Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktion
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
ITBO930205A1 (it) Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
DE59609508D1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
IL118218A (en) Pharmaceutical compositions containing sarcodictyins
TR200401810T4 (tr) Kısırlık tedavisinde fsh'ın kullanılması
TR199801439T2 (xx) Herpes simpleks enfeksiyonlar�n�n kombine terapisinde n�kleosit analoglar�.
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
TR199901237T2 (xx) Bir tienilsiklohegzilamin t�revinin tedavide yeni uygulamas�.
RU96102209A (ru) Лекарственное средство
ATE257377T1 (de) Blister enthaltend ein transdermales therapeutisches system und eine einzeldosierte darreichungsform

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee